These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23735152)

  • 21. Effects of cinacalcet on vascular calcification in haemodialysis patients.
    Almirall J; Gallardo X; Castañé E
    Nephrol Dial Transplant; 2010 Aug; 25(8):2800. PubMed ID: 20501465
    [No Abstract]   [Full Text] [Related]  

  • 22. Cinacalcet and cardiovascular mortality in hemodialysis patients.
    Klein GL
    Kidney Int; 2010 Oct; 78(8):820. PubMed ID: 20877380
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism.
    Dorsch O
    Nephrol Dial Transplant; 2007 Feb; 22(2):637-40. PubMed ID: 17095580
    [No Abstract]   [Full Text] [Related]  

  • 24. Cinacalcet: will it play a role in reducing cardiovascular events?
    Karohl C; Raggi P
    Future Cardiol; 2012 May; 8(3):357-70. PubMed ID: 22420327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
    Stubbs JR; Wetmore JB
    Semin Dial; 2011; 24(3):298-306. PubMed ID: 21682772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
    Raggi P; Chertow GM; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Floege J;
    Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of mineral and bone disorder in chronic kidney disease: quo vadis?
    Nakai K; Komaba H; Fukagawa M
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S2-6. PubMed ID: 19765254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
    Yokoyama K
    Clin Calcium; 2010 Jul; 20(7):1012-20. PubMed ID: 20585179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cervical tumoral calcinosis with secondary hyperparathyroidism in a chronic hemodialysis patient.
    Sunder S; Verma H; Venkataramanan K
    Hemodial Int; 2013 Jul; 17(3):458-62. PubMed ID: 23072397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring.
    Nowack R; Wachtler P
    Clin Lab; 2006; 52(11-12):583-7. PubMed ID: 17175888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols.
    Chertow GM; Lu ZJ; Xu X; Knight TG; Goodman WG; Bushinsky DA; Block GA
    Hemodial Int; 2012 Apr; 16(2):188-97. PubMed ID: 22118402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries.
    Iannazzo S; Carsi M; Chiroli S
    Appl Health Econ Health Policy; 2012 Mar; 10(2):127-38. PubMed ID: 22268372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism.
    Jean G; Chazot C; Charra B
    Nephrol Dial Transplant; 2007 Jul; 22(7):2102-3. PubMed ID: 17395648
    [No Abstract]   [Full Text] [Related]  

  • 38. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
    Fukagawa M; Komaba H; Kakuta T
    Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
    Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.